Compare BYND & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | IVVD |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 201.9M |
| IPO Year | 2018 | 2021 |
| Metric | BYND | IVVD |
|---|---|---|
| Price | $14.77 | $1.00 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $0.83 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 34.0M | 3.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.69 | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,496,000.00 | $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | $1.36 | $41.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.40 | $0.52 |
| 52 Week High | $15.20 | $3.07 |
| Indicator | BYND | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 88.60 | 69.89 |
| Support Level | $0.66 | $0.69 |
| Resistance Level | N/A | $1.01 |
| Average True Range (ATR) | 0.76 | 0.08 |
| MACD | 1.53 | 0.05 |
| Stochastic Oscillator | 95.81 | 89.30 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.